The efficacy and tolerability of nebivolol in hypertensive African American patients.

Elijah Saunders, William Smith, Karen B. DeSalvo, Will A. Sullivan

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Hypertensive African Americans often respond poorly to beta-blocker monotherapy, compared with whites. There is evidence, however, that suggests that this response may be different if beta-blockers with vasodilating effects are used. This 12-week, multi-center, double-blind, randomized placebo-controlled study assessed the antihypertensive efficacy and safety of nebivolol, a cardioselective, vasodilating beta1-blocker, at doses of 2.5, 5, 10, 20, or 40 mg once daily in 300 African American patients with stage I or II hypertension (mean sitting diastolic blood pressure [SiDBP] > or =95 mm Hg and < or =109 mm Hg). The primary efficacy end point was the baseline-adjusted change in trough mean SiDBP. After 12 weeks, nebivolol significantly reduced least squares mean SiDBP (P< or =.004) at all doses of 5 mg and higher and sitting systolic blood pressure (P< or =.044) at all doses 10 mg and higher, compared with placebo. The drug was safe and well-tolerated, with no significant difference in the incidence of adverse events compared with placebo. Nebivolol monotherapy provides antihypertensive efficacy, with few significant adverse effects, in hypertensive African Americans.

Original languageEnglish (US)
Pages (from-to)866-875
Number of pages10
JournalJournal of clinical hypertension (Greenwich, Conn.)
Volume9
Issue number11
DOIs
StatePublished - Jan 1 2007

Fingerprint

Nebivolol
African Americans
Blood Pressure
Placebos
Antihypertensive Agents
Least-Squares Analysis

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

The efficacy and tolerability of nebivolol in hypertensive African American patients. / Saunders, Elijah; Smith, William; DeSalvo, Karen B.; Sullivan, Will A.

In: Journal of clinical hypertension (Greenwich, Conn.), Vol. 9, No. 11, 01.01.2007, p. 866-875.

Research output: Contribution to journalArticle

@article{cf2a1ccb7e1a4bd28d5e1a733a4ce698,
title = "The efficacy and tolerability of nebivolol in hypertensive African American patients.",
abstract = "Hypertensive African Americans often respond poorly to beta-blocker monotherapy, compared with whites. There is evidence, however, that suggests that this response may be different if beta-blockers with vasodilating effects are used. This 12-week, multi-center, double-blind, randomized placebo-controlled study assessed the antihypertensive efficacy and safety of nebivolol, a cardioselective, vasodilating beta1-blocker, at doses of 2.5, 5, 10, 20, or 40 mg once daily in 300 African American patients with stage I or II hypertension (mean sitting diastolic blood pressure [SiDBP] > or =95 mm Hg and < or =109 mm Hg). The primary efficacy end point was the baseline-adjusted change in trough mean SiDBP. After 12 weeks, nebivolol significantly reduced least squares mean SiDBP (P< or =.004) at all doses of 5 mg and higher and sitting systolic blood pressure (P< or =.044) at all doses 10 mg and higher, compared with placebo. The drug was safe and well-tolerated, with no significant difference in the incidence of adverse events compared with placebo. Nebivolol monotherapy provides antihypertensive efficacy, with few significant adverse effects, in hypertensive African Americans.",
author = "Elijah Saunders and William Smith and DeSalvo, {Karen B.} and Sullivan, {Will A.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1111/j.1524-6175.2007.07548.x",
language = "English (US)",
volume = "9",
pages = "866--875",
journal = "Journal of Clinical Hypertension",
issn = "1524-6175",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - The efficacy and tolerability of nebivolol in hypertensive African American patients.

AU - Saunders, Elijah

AU - Smith, William

AU - DeSalvo, Karen B.

AU - Sullivan, Will A.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Hypertensive African Americans often respond poorly to beta-blocker monotherapy, compared with whites. There is evidence, however, that suggests that this response may be different if beta-blockers with vasodilating effects are used. This 12-week, multi-center, double-blind, randomized placebo-controlled study assessed the antihypertensive efficacy and safety of nebivolol, a cardioselective, vasodilating beta1-blocker, at doses of 2.5, 5, 10, 20, or 40 mg once daily in 300 African American patients with stage I or II hypertension (mean sitting diastolic blood pressure [SiDBP] > or =95 mm Hg and < or =109 mm Hg). The primary efficacy end point was the baseline-adjusted change in trough mean SiDBP. After 12 weeks, nebivolol significantly reduced least squares mean SiDBP (P< or =.004) at all doses of 5 mg and higher and sitting systolic blood pressure (P< or =.044) at all doses 10 mg and higher, compared with placebo. The drug was safe and well-tolerated, with no significant difference in the incidence of adverse events compared with placebo. Nebivolol monotherapy provides antihypertensive efficacy, with few significant adverse effects, in hypertensive African Americans.

AB - Hypertensive African Americans often respond poorly to beta-blocker monotherapy, compared with whites. There is evidence, however, that suggests that this response may be different if beta-blockers with vasodilating effects are used. This 12-week, multi-center, double-blind, randomized placebo-controlled study assessed the antihypertensive efficacy and safety of nebivolol, a cardioselective, vasodilating beta1-blocker, at doses of 2.5, 5, 10, 20, or 40 mg once daily in 300 African American patients with stage I or II hypertension (mean sitting diastolic blood pressure [SiDBP] > or =95 mm Hg and < or =109 mm Hg). The primary efficacy end point was the baseline-adjusted change in trough mean SiDBP. After 12 weeks, nebivolol significantly reduced least squares mean SiDBP (P< or =.004) at all doses of 5 mg and higher and sitting systolic blood pressure (P< or =.044) at all doses 10 mg and higher, compared with placebo. The drug was safe and well-tolerated, with no significant difference in the incidence of adverse events compared with placebo. Nebivolol monotherapy provides antihypertensive efficacy, with few significant adverse effects, in hypertensive African Americans.

UR - http://www.scopus.com/inward/record.url?scp=38449115960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449115960&partnerID=8YFLogxK

U2 - 10.1111/j.1524-6175.2007.07548.x

DO - 10.1111/j.1524-6175.2007.07548.x

M3 - Article

C2 - 17978594

AN - SCOPUS:38449115960

VL - 9

SP - 866

EP - 875

JO - Journal of Clinical Hypertension

JF - Journal of Clinical Hypertension

SN - 1524-6175

IS - 11

ER -